BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

It was determined that substitution at the C6-position of the benzo[b]thiophene core with a three-atom spacer yielded optimal HDAC1 inhibition and anti-proliferative activity in murine erythroleukemia (SC-9) cells.

BindingDB. BindingDB .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17576064.001).

[ISSN] 0960-894X

[Journal-full-title] Bioorganic & medicinal chemistry letters

[ISO-abbreviation] Bioorg. Med. Chem. Lett.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; 0 / Thiophenes

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The measured gas concentrations were generally below the permissible exposure limits (PELs) established by the Occupational Safety and Health Administration (OSHA) throughout the year except for the NH3 concentrations in cold weather (December, January, and February).

Hazardous Substances Data Bank. Carbon dioxide .

Hazardous Substances Data Bank. Ammonia .

Hazardous Substances Data Bank. HYDROGEN SULFIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20437782.001).

[ISSN] 1096-2247

[Journal-full-title] Journal of the Air & Waste Management Association (1995)

[ISO-abbreviation] J Air Waste Manag Assoc

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 142M471B3J / Carbon Dioxide; 7664-41-7 / Ammonia; YY9FVM7NSN / Hydrogen Sulfide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gab1 transduces PI3K-mediated erythropoietin signals to the Erk pathway and regulates erythropoietin-dependent proliferation and survival of erythroid cells.

Knockdown of Gab1 by the introduction of the Gab1 siRNA expression vector into F-36P human erythroleukemia (F-36P-Gab1-siRNA) cells resulted in a reduction of cell proliferation and survival in response to EPO.

LY294002 inhibited EPO-induced tyrosine phosphorylation of Gab1 and its association with Grb2 in human primary EPO-sensitive erythroid cells.

Taken together, these results suggest that Gab1 couples PI3K-mediated EPO signals with the Ras/Erk pathway and that Gab1 plays an important role in EPOR-mediated signal transduction involved in the proliferation and survival of erythroid cells.

[MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Erythroid Cells / cytology. Erythropoietin / metabolism. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Phosphatidylinositol 3-Kinases / metabolism

[MeSH-minor] Apoptosis. Cell Line, Tumor. Cell Proliferation. Chromones / pharmacology. Enzyme Inhibitors / pharmacology. GRB2 Adaptor Protein / metabolism. Gene Knockdown Techniques. Humans. Janus Kinase 2 / antagonists & inhibitors. Janus Kinase 2 / metabolism. Leukemia, Erythroblastic, Acute / metabolism. Morpholines / pharmacology. Protein Tyrosine Phosphatase, Non-Receptor Type 11 / metabolism. Receptors, Erythropoietin / metabolism. SOS1 Protein / metabolism

National BioResource Project. culture/stock collections - NBRP resources .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19665053.001).

[ISSN] 1873-3913

[Journal-full-title] Cellular signalling

[ISO-abbreviation] Cell. Signal.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Chromones; 0 / Enzyme Inhibitors; 0 / GAB1 protein, human; 0 / GRB2 Adaptor Protein; 0 / GRB2 protein, human; 0 / Morpholines; 0 / Receptors, Erythropoietin; 0 / SOS1 Protein; 11096-26-7 / Erythropoietin; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The development of a low-cost, simple colorimetric sensor array capable of the detection and identification of toxic gases is reported.

Striking visual identification of 3 toxic gases has been shown at the IDLH (immediately dangerous to life and health) concentration, at the PEL (permissible exposure level), and at a level well below the PEL.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. Sulfur dioxide .

Hazardous Substances Data Bank. Ammonia .

Hazardous Substances Data Bank. CHLORINE .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nature. 2000 Aug 17;406(6797):710-3 [10963592.001]

[Cites] Nat Mater. 2003 Jan;2(1):19-24 [12652667.001]

[Cites] Acc Chem Res. 2004 Sep;37(9):663-72 [15379582.001]

[Cites] MRS Bull. 2004 Oct;29(10):720-5 [15991401.001]

[Cites] Angew Chem Int Ed Engl. 2005 Jul 18;44(29):4528-32 [16003792.001]

[Cites] Anal Chem. 2009 Aug 1;81(15):6526-33 [20337402.001]

[Cites] Anal Chem. 2006 Jun 1;78(11):3591-600 [16737212.001]

[Cites] J Agric Food Chem. 2006 Jul 12;54(14):4925-31 [16819897.001]

[Cites] J Agric Food Chem. 2007 Jan 24;55(2):237-42 [17227048.001]

[Cites] J Org Chem. 2007 Feb 2;72(3):687-99 [17253783.001]

[Cites] Org Lett. 2008 Oct 16;10(20):4405-8 [18783231.001]

[Cites] J Am Chem Soc. 2005 Aug 24;127(33):11548-9 [16104700.001]

(PMID = 19918616.001).

[ISSN] 1364-5528

[Journal-full-title] The Analyst

[ISO-abbreviation] Analyst

[Language] ENG

[Grant] United States / NIEHS NIH HHS / ES / ES016011-03; United States / NIEHS NIH HHS / ES / U01 ES016011; United States / NIEHS NIH HHS / ES / U01 ES016011-03; United States / NIEHS NIH HHS / ES / U01ES016011

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Air Pollutants; 0 / Coloring Agents; 0 / Gases; 0 / Membranes, Artificial; 0UZA3422Q4 / Sulfur Dioxide; 4R7X1O2820 / Chlorine; 7664-41-7 / Ammonia

[Other-IDs] NLM/ NIHMS229255; NLM/ PMC2947824

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Here we have used Friend murine leukemia virus (F-MuLV)-induced erythroleukemia to investigate factors of the splenic microenvironment that may make it fertile for the expansion and survival of malignant erythroblasts.

Cytokine protein arrays revealed that F-MuLV-infected splenocytes secreted elevated levels of interleukin-6 (IL-6), vascular endothelial growth factor-A (VEGF-A), macrophage chemoattractant protein-5 (MCP-5), soluble tumor necrosis factor receptor-1 (sTNFR1), IL-12p70, tumor necrosis factor-alpha (TNF-alpha), and IL-2 over normal splenocytes.

Furthermore, in vivo administration of a neutralizing antibody to VEGF-A extended survival times of erythroleukemic mice in comparison with controls.

These findings suggest that VEGF-A and MCP-5 are potentially pivotal paracrine mediators occurring within the diseased splenic microenvironment capable of promoting disease acceleration and expansion of erythroleukemic blasts.

COS Scholar Universe. author profiles.

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood Cells. 1981;7(1):133-44 [7187746.001]

[Cites] Clin Haematol. 1983 Jun;12(2):505-16 [6352114.001]

[Cites] Curr Top Microbiol Immunol. 1989;148:1-42 [2684547.001]

[Cites] Exp Hematol. 1990 Aug;18(7):775-84 [1696206.001]

[Cites] Leuk Lymphoma. 1993 Jul;10(4-5):245-64 [8220125.001]

[Cites] Eur J Haematol. 1996 Jan-Feb;56(1-2):45-53 [8599993.001]

[Cites] J Exp Med. 1997 Jan 6;185(1):99-109 [8996246.001]

[Cites] Am J Pathol. 1997 Mar;150(3):815-21 [9060819.001]

[Cites] Leukemia. 1997 Apr;11 Suppl 3:474-7 [9209429.001]

[Cites] Virchows Arch. 1997 Jun;430(6):433-43 [9230908.001]

[Cites] Eur J Cell Biol. 1997 Dec;74(4):321-8 [9438127.001]

[Cites] Leuk Lymphoma. 1997 Nov;27(5-6):375-86 [9477120.001]

[Cites] Blood. 1998 Mar 1;91(5):1548-55 [9473219.001]

[Cites] Blood. 1998 Dec 15;92(12):4798-807 [9845547.001]

[Cites] Mol Cell Biol. 1999 Jun;19(6):4452-64 [10330185.001]

[Cites] Virology. 1964 Nov;24:513-8 [14227060.001]

[Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):712-9 [15701860.001]

[Cites] Exp Hematol. 2000 Jun;28(6):700-6 [10880756.001]

[Cites] Clin Cancer Res. 2000 Aug;6(8):3282-9 [10955814.001]

[Cites] J Immunol Methods. 2001 Jun 1;252(1-2):131-8 [11334972.001]

[Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]

[Cites] Blood. 2001 Jun 1;97(11):3658-61 [11369666.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10857-62 [11553814.001]

[Cites] Ann Hematol. 2001 Dec;80(12):695-705 [11797109.001]

[Cites] Blood. 2002 Mar 15;99(6):2179-84 [11877295.001]

[Cites] Blood. 2002 Apr 1;99(7):2532-40 [11895790.001]

[Cites] Cancer Res. 2002 Mar 15;62(6):1838-46 [11912163.001]

[Cites] Am J Hematol. 2002 May;70(1):22-30 [11994978.001]

[Cites] J Mol Med (Berl). 2003 Jan;81(1):20-31 [12545246.001]

[Cites] APMIS. 2002 Dec;110(12):899-912 [12645669.001]

[Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]

[Cites] Anticancer Res. 2003 May-Jun;23(3A):2159-66 [12894591.001]

[Cites] Cancer Res. 2003 Aug 1;63(15):4342-6 [12907602.001]

[Cites] Cancer Sci. 2003 Dec;94(12):1034-41 [14662017.001]

[Cites] Cancer. 1978 Aug;42(2 Suppl):946-56 [356959.001]

[Cites] Exp Hematol. 1985 Aug;13(7):623-8 [3861325.001]

(PMID = 15701719.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA-41233

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Angiogenic Proteins; 0 / Antibodies, Monoclonal; 0 / Cytokines; 0 / Inflammation Mediators; 0 / Monocyte Chemoattractant Proteins; 0 / Vascular Endothelial Growth Factor A

[Other-IDs] NLM/ PMC1895028

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Apoptosis induced by NNAMB, a novel polyamine conjugate, in human erythroleukemia K562 cells and its mechanism].

OBJECTIVE: To investigate the apoptosis-inducing effects of NNAMB, a novel polyamine conjugate, in erythroleukemia K562 cells and its molecular mechanism.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19062712.001).

[ISSN] 0253-3766

[Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]

[ISO-abbreviation] Zhonghua Zhong Liu Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Anthracenes; 0 / NNAMB compound; 0 / Polyamines; 9007-43-6 / Cytochromes c; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9; U87FK77H25 / Spermidine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sequences of polycythemia-type Friend spleen focus-forming virus in clone-745-derived mouse erythroleukemia cells.

Friend leukemia virus complex consists of a replication-competent virus plus one of two replication-incompetent viruses, spleen focus-forming virus anemia virus or spleen focus-forming virus polycythemia virus.

The replication-incompetent viruses induce rapid malignant transformation of erythroid precursor cells.

However, lines containing the anemia-type virus require erythropoietin and another agent such as dimethyl sulfoxide for optimal erythrodifferentiation, whereas those containing the polycythemia-type virus do not require or respond to erythropoietin.

Sequence analysis demonstrates that they contain the polycythemia-type virus and not the anemia-type virus.

[MeSH-minor] Animals. Cell Differentiation. Cell Line, Transformed. Leukemia, Experimental / virology. Mice. Molecular Sequence Data. RNA, Viral / genetics. Retroviridae Infections / virology. Sequence Analysis, RNA. Tumor Virus Infections / virology

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19347245.001).

[ISSN] 1432-8798

[Journal-full-title] Archives of virology

[ISO-abbreviation] Arch. Virol.

[Language] eng

[Databank-accession-numbers] GENBANK/ FJ556972/ FJ556973

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Austria

[Chemical-registry-number] 0 / RNA, Viral

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: The LIM-finger protein LMO2 forms a transcription factor complex with other hematopoietic regulator proteins, such as TAL1 (SCL), LDB1, GATA1, 2, and 3, in the promoters of several erythroid genes.

In vivo hematopoiesis in transgenic mice with wild-type and LIM-modified Lmo2 was studied morphologically and by measuring the progenitor cells in fetal liver.

Their effects on the erythroid differentiation of the dimethylsulfoxide (DMSO)-induced murine erythroleukemia (MEL) cells were evaluated.

Overexpression of wild-type LMO2 is known to have dominant negative inhibitory effects on erythropoietic development.

DMSO-induced erythroid differentiation of the MEL cells was inhibited by the overexpressed LMO2 with mutant LIM2 but not by the LMO2 with modified LIM1.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15911088.001).

[ISSN] 0301-472X

[Journal-full-title] Experimental hematology

[ISO-abbreviation] Exp. Hematol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / Lmo2 protein, mouse; 0 / Metalloproteins

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

These ultrasmall SWNTs are fabricated in the elliptical nanochannels of an AlPO-11 (AEL) single crystal.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18764364.001).

[ISSN] 0031-9007

[Journal-full-title] Physical review letters

[ISO-abbreviation] Phys. Rev. Lett.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The accumulation of Hsp70 and Hdj 1 in human erythroleukemia K562 cells was stimulated by heat stress (43 degrees C, 60 min).

The level of Hsp70 chaperone activity in cell extracts was estimated using original technique.

The results of the study indicate that Hsp70 chaperone activity is regulated by the level of its cochaperones, especially Hdj 1.

This finding confirms the possibility of using peptide approach for regulation of Hsp70 function at the cellular and organismal levels.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16706166.001).

[ISSN] 0041-3771

[Journal-full-title] Tsitologiia

[ISO-abbreviation] Tsitologiia

[Language] rus

[Publication-type] Comparative Study; English Abstract; Journal Article

[Publication-country] Russia (Federation)

[Chemical-registry-number] 0 / BCL2-associated athanogene 1 protein; 0 / Culture Media; 0 / DNA-Binding Proteins; 0 / DNAJB1 protein, human; 0 / HSP40 Heat-Shock Proteins; 0 / HSP70 Heat-Shock Proteins; 0 / Transcription Factors; 8L70Q75FXE / Adenosine Triphosphate

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Exogenous wild-type p53 gene improved survival of nude mice injected with murine erythroleukemia cell line through amelioration of hemorheological changes.

OBJECTIVES: Previous investigations have shown that human wild-type p53 gene (WTp53) inhibits the growth of leukemia and tumor cells in vitro.

In the present study, the authors used nude mice and examined the therapeutic role of p53 gene for erythroleukemia in vivo in the absence of MHC effects.

METHODS: The nude mice were injected with murine erythroleukemia cells (MEL), MEL cells transfected with wild-type p53 gene (MEL-W), and MEL cells transfected with mutated p53 gene (MEL-M).

RESULTS: The results showed that WTp53 restrained the growth of erythroleukemia cells in vivo and reduced the erythroleukemia tumorigenesis in the microcirculation by improving the hemorheological and biophysical properties of MEL cells, which helped to prolong the life span of nude mice suffering from erythroleukemia.

CONCLUSION: These results contribute to our knowledge on the use of wild-type p53 gene for the treatment of erythroleukemia disease.

[MeSH-major] Leukemia, Erythroblastic, Acute / pathology. Leukemia, Erythroblastic, Acute / physiopathology. Tumor Suppressor Protein p53 / genetics

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17365670.001).

[ISSN] 1073-9688

[Journal-full-title] Microcirculation (New York, N.Y. : 1994)

[ISO-abbreviation] Microcirculation

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Tumor Suppressor Protein p53

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We investigated whether human erythroleukemia (HEL) cells were able to bind, metabolise and transport the main endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG).

Indeed, 2-AG itself drove HEL cells towards megakaryocytic differentiation, as it enhanced expression of beta3 integrin subunit, a megakaryocyte/platelet surface antigen, and glycoprotein VI, a late marker of megakaryocytes; in parallel, it reduced the amount of messenger RNA encoding for glycophorin A, a marker of erythroid phenotype.

In addition, classical inducers of megakaryocyte differentiation reduced 2-AG synthesis (although they did not affect the binding efficiency of CB(2) receptors), suggesting that levels of this endocannabinoid may be critical for committing HEL cells towards the megakaryocytic lineage.

[MeSH-major] Arachidonic Acids / pharmacology. Cannabinoid Receptor Modulators / biosynthesis. Cannabinoid Receptor Modulators / pharmacology. Cell Differentiation / drug effects. Endocannabinoids. Gene Expression Regulation / drug effects. Glycerides / pharmacology. Megakaryocytes / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2004 Jul 15;104(2):526-34 [15039279.001]

[Cites] Cell. 1995 Jan 27;80(2):179-85 [7834738.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10819-24 [12136125.001]

[Cites] Pharmacol Ther. 1997;74(2):129-80 [9336020.001]

[Cites] J Clin Endocrinol Metab. 2006 Aug;91(8):3171-80 [16684820.001]

[Cites] Eur J Biochem. 2004 May;271(10 ):1827-34 [15128293.001]

[Cites] Blood. 2002 Dec 1;100(12 ):4040-8 [12393387.001]

[Cites] Eur J Pharmacol. 2004 Jan 26;484(2-3):249-57 [14744610.001]

[Cites] Neuroscience. 2003;119(2):481-96 [12770562.001]

[Cites] Trends Pharmacol Sci. 2006 Mar;27(3):134-40 [16476494.001]

[Cites] Thromb Haemost. 2003 Feb;89(2):340-7 [12574815.001]

[Cites] Nature. 2000 Mar 9;404(6774):193-7 [10724173.001]

[Cites] Free Radic Biol Med. 2007 Mar 1;42(5):608-16 [17291984.001]

[Cites] Blood. 1987 Dec;70(6):1764-72 [3676512.001]

[Cites] Curr Pharm Des. 2006;12 (18):2319-25 [16787257.001]

[Cites] J Cell Sci. 2005 Oct 1;118(Pt 19):4393-404 [16144868.001]

[Cites] Eur J Biochem. 2001 Feb;268(3):819-25 [11168423.001]

[Cites] J Neurochem. 1997 Aug;69(2):631-8 [9231721.001]

[Cites] EMBO J. 1984 Feb;3(2):453-9 [6201359.001]

[Cites] Handb Exp Pharmacol. 2005;(168):599-625 [16596789.001]

[Cites] Nat Rev Neurosci. 2003 Nov;4(11):873-84 [14595399.001]

[Cites] Science. 2005 Oct 14;310(5746):329-32 [16224028.001]

[Cites] AAPS J. 2006;8(2):E409-12 [16808043.001]

[Cites] J Exp Med. 1981 Jul 1;154(1):88-100 [6788894.001]

[Cites] J Pharmacol Exp Ther. 2002 Jan;300(1):339-45 [11752134.001]

[Cites] FEBS Lett. 1999 Mar 26;447(2-3):277-82 [10214961.001]

[Cites] J Biol Chem. 2000 Jan 7;275(1):605-12 [10617657.001]

[Cites] J Cell Biol. 2003 Nov 10;163(3):463-8 [14610053.001]

[Cites] Mini Rev Med Chem. 2006 Mar;6(3):257-68 [16515464.001]

[Cites] Annu Rev Biochem. 2005;74:411-32 [15952893.001]

[Cites] Nature. 2006 Nov 9;444(7116):208-12 [17093448.001]

[Cites] J Biol Chem. 2004 Feb 13;279(7):5298-305 [14634025.001]

[Cites] Cell Biol Int. 2004;28(5):403-10 [15193284.001]

[Cites] Blood. 2003 Feb 15;101(4):1336-43 [12406867.001]

(PMID = 18820887.001).

[ISSN] 0946-2716

[Journal-full-title] Journal of molecular medicine (Berlin, Germany)

[ISO-abbreviation] J. Mol. Med.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Arachidonic Acids; 0 / Cannabinoid Receptor Modulators; 0 / Endocannabinoids; 0 / Glycerides; 0 / Polyunsaturated Alkamides; 8D239QDW64 / glyceryl 2-arachidonate; UR5G69TJKH / anandamide

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) is a rare B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV).

PEL is poorly responsive to standard cytotoxic chemotherapy and portends a poor survival.

It is known that KSHV encodes two lytic genes, ORF36 (phosphotransferase) and KSHV ORF21 (thymidine kinase), which can phosphorylate ganciclovir and azidothymidine, respectively.

Here, we have explored whether these genes can be used as therapeutic targets for PEL.

PEL arises in pleural spaces and other effusions that provide a hypoxic environment.

Based on Northern blot analysis, exposure of PEL cells to hypoxia up-regulated the expression of both ORF36 and ORF21.

Using a newly developed nonradioactive reverse-phase high-performance liquid chromatography/mass spectrometry method to separate and quantify the phosphorylated forms of ganciclovir and azidothymidine, we found that PEL cells exposed to hypoxia produced increased amounts of the toxic triphosphates of these drugs.

Moreover, we found that hypoxia increased the cell toxicity of ganciclovir and azidothymidine in PEL cells but had no significant effect on the herpesvirus-negative cell line CA46.

These findings may have clinical applicability in the development of effective therapies for PEL or other KSHV-related malignancies.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ZIDOVUDINE .

Hazardous Substances Data Bank. GANCICLOVIR .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17638913.001).

[ISSN] 0008-5472

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] eng

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antiviral Agents; 4B9XT59T7S / Zidovudine; P9G3CKZ4P5 / Ganciclovir

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The mean concentration of silica before 1986 was an extremely high level of 8.6 mg/m(3), and then remarkably dropped after 1986, with the level of 2.4 mg/m(3) from 1986 to 1989, 2.7 mg/m(3) from 1990 to 2002 and 2.7 mg/m(3) from 2003 to 2008.

Silica concentrations among jobs were significantly different, with highest level in melting (4.4 mg/m(3)), followed by cast shakeout and finishing (3.4 mg/m(3)), pouring (3.4 mg/m(3)), sand preparation (2.4 mg/m(3)), moulding (2.1 mg/m(3)) and core-making (1.7 mg/m(3)).

Mean concentration of asbestos dust in melting was a relative high level of 2.0 mg/m(3).

Benzene and its homologues existed in cast shakeout and finishing, and the level of benzene, toluene, xylene was 0.2 mg/m(3), 0.1 mg/m(3) and 1.3 mg/m(3), respectively.

Mean concentration of benzo(a) pyrene was a low level of 1.80 x 10(-4) microg/m(3).

Intensity of heat stress was high in melting, pouring and cast shakeout and finishing, with the level of 30 degrees C, 29 degrees C and 26 degrees C, respectively.

Noise was high in cast shakeout and finishing and core-making, with the level of 93.1 dB(A) and 89.5 dB(A), respectively.

CONCLUSION: Occupational hazards in environment of the foundry are diversified and their concentrations exceed permissible exposure limits stipulated by the national occupational hygienic standards.

[MeSH-major] Dust / analysis. Hazardous Substances / analysis. Occupational Exposure

MedlinePlus Health Information. consumer health - Occupational Health.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20465956.001).

[ISSN] 1001-9391

[Journal-full-title] Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases

[ISO-abbreviation] Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Dust; 0 / Hazardous Substances

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute erythroid leukemia (AML-M6) - Is it rare?

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27265109.001).

[ISSN] 1300-7777

[Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology

[ISO-abbreviation] Turk J Haematol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Turkey

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

This analysis highlighted both known differences in serum and citrated plasma such as fibrinogens, and reproducible differences in peptide abundances from proteins such as soluble activin receptor-like kinase 7b and glycoprotein m6b.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nat Biotechnol. 2001 Mar;19(3):242-7 [11231557.001]

[Cites] Proteomics. 2004 Mar;4(3):656-68 [14997489.001]

[Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]

[Cites] Proteomics. 2002 Mar;2(3):288-305 [11921445.001]

[Cites] Proteomics. 2002 May;2(5):513-23 [11987125.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11049-54 [12177431.001]

[Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]

[Cites] Anal Chem. 2002 Nov 1;74(21):5593-9 [12433093.001]

[Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]

[Cites] Mol Cell Proteomics. 2002 Dec;1(12):947-55 [12543931.001]

[Cites] Nat Biotechnol. 2003 Mar;21(3):247-54 [12610571.001]

[Cites] J Proteome Res. 2003 Jan-Feb;2(1):43-50 [12643542.001]

[Cites] J Proteome Res. 2002 Sep-Oct;1(5):459-65 [12645918.001]

[Cites] J Mol Diagn. 2003 May;5(2):73-81 [12707371.001]

[Cites] EHP Toxicogenomics. 2003 Jan;111(1T):1-5 [12735104.001]

[Cites] Proteomics. 2003 Jul;3(7):1345-64 [12872236.001]

[Cites] J Proteome Res. 2003 Jul-Aug;2(4):383-93 [12938928.001]

[Cites] Mol Cell Proteomics. 2003 Oct;2(10):1096-103 [12917320.001]

[Cites] Nature. 2003 Oct 30;425(6961):905 [14586448.001]

[Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]

[Cites] Mol Cell Proteomics. 2004 Jan;3(1):1-9 [14608001.001]

[Cites] J Am Soc Mass Spectrom. 2004 Feb;15(2):212-32 [14766289.001]

[Cites] Anal Chem. 2004 Feb 15;76(4):1134-44 [14961748.001]

[Cites] J Proteome Res. 2004 Jan-Feb;3(1):68-75 [14998165.001]

[Cites] Mol Cell Proteomics. 2004 Apr;3(4):311-26 [14718574.001]

[Cites] Mol Cell Proteomics. 2004 Apr;3(4):298-301 [14747694.001]

[Cites] J Proteome Res. 2004 Mar-Apr;3(2):163 [15113090.001]

[Cites] Proteomics. 2004 May;4(5):1235-40 [15188391.001]

[Cites] Mol Cell Proteomics. 2004 Jun;3(6):608-14 [15034119.001]

[Cites] Proteomics. 2004 Jul;4(7):2125-50 [15221774.001]

[Cites] J Proteome Res. 2004 May-Jun;3(3):364-82 [15253417.001]

[Cites] Nat Biotechnol. 2004 Aug;22(8):985-92 [15258593.001]

[Cites] J Proteome Res. 2004 Jul-Aug;3(4):760-9 [15359729.001]

[Cites] Anal Chem. 2004 Sep 15;76(18):5345-53 [15362891.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13417-22 [15347803.001]

[Cites] Rapid Commun Mass Spectrom. 2004;18(19):2201-7 [15384137.001]

[Cites] Proc Natl Acad Sci U S A. 1977 Dec;74(12):5421-5 [271964.001]

[Cites] EMBO J. 1990 Mar;9(3):797-803 [2311582.001]

[Cites] Methods Mol Biol. 1999;112:553-69 [10027276.001]

[Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]

[Cites] Biotechniques. 2004 Oct;37(4):621-4, 626-33, 636 passim [15517975.001]

[Cites] Anal Chem. 2004 Dec 1;76(23):6853-60 [15571333.001]

[Cites] IEEE Comput Graph Appl. 2004 Sep-Oct;24(5):10-5 [15628094.001]

[Cites] Anal Chem. 2005 Jan 15;77(2):400-6 [15649034.001]

[Cites] J Proteome Res. 2005 Jan-Feb;4(1):53-62 [15707357.001]

[Cites] Mol Cell Proteomics. 2005 May;4(5):700-9 [15753121.001]

[Cites] Anal Chem. 2001 Dec 1;73(23):5683-90 [11774908.001]

(PMID = 16052625.001).

[ISSN] 1615-9853

[Journal-full-title] Proteomics

[ISO-abbreviation] Proteomics

[Language] ENG

[Grant] United States / NCRR NIH HHS / RR / P41 RR018522; United States / NCI NIH HHS / CA / CA78722; United States / NCRR NIH HHS / RR / RR18522

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.

[Publication-country] Germany

[Chemical-registry-number] 0 / Blood Proteins; 0 / Ions; 0 / Peptides; 0 / Proteins; 0 / Proteome; 9001-32-5 / Fibrinogen; EC 3.4.21.4 / Trypsin

[Other-IDs] NLM/ NIHMS15646; NLM/ PMC2041806

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Schizophrenia is not associated with the ERBB3 gene in a Han Chinese population sample: Results from case-control and family-based studies.

ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3), encoding a receptor of neuregulin-1 (NRG1), has been considered a functional candidate gene for schizophrenia susceptibility.

In order to investigate a relationship between ERBB3 gene and schizophrenia in the Chinese population, case-control and family-based studies were carried out in 470 cases matched by controls, and in 532 family trios.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4746-51 [11296301.001]

[Cites] Nat Genet. 2001 Aug;28(4):386-8 [11455389.001]

[Cites] Lancet. 2003 Sep 6;362(9386):798-805 [13678875.001]

[Cites] Biochem Biophys Res Commun. 2005 Sep 2;334(3):817-23 [16023997.001]

[Cites] Ann Hum Genet. 1995 Jan;59(Pt 1):97-105 [7762987.001]

[Cites] Am J Med Genet B Neuropsychiatr Genet. 2007 Jan 5;144B(1):113-6 [16958035.001]

[Cites] Neurosci Res. 2007 Apr;57(4):574-8 [17275115.001]

[Cites] Behav Brain Funct. 2007;3:31 [17598910.001]

[Cites] Hum Mol Genet. 2006 Jun 15;15(12):1995-2002 [16687441.001]

(PMID = 21637446.001).

[ISSN] 1678-4685

[Journal-full-title] Genetics and molecular biology

[ISO-abbreviation] Genet. Mol. Biol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Brazil

[Other-IDs] NLM/ PMC3036886

[Keywords] NOTNLM ; ERBB3 gene / schizophrenia

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) is a rare type of lymphoma related to herpesvirus-8 (HHV-8), and considered an AIDS-defining condition.

The authors describe a case of PEL with cardiac involvement occurring in an HIV-positive patient treated with HAART and chemotherapy, who achieved complete remission and long survival.

[MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. HIV Infections / drug therapy. HIV Long-Term Survivors. Heart Neoplasms / secondary. Lymphoma, Primary Effusion / complications. Lymphoma, Primary Effusion / diagnosis

Genetic Alliance. consumer health - Primary effusion lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18845471.001).

[ISSN] 1386-6532

[Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

[ISO-abbreviation] J. Clin. Virol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Netherlands

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group.

BACKGROUND: Myelodysplastic syndromes (MDS), acute erythroleukemia (FAB M6), and acute megakaryocytic leukemia (FAB M7) have overlapping features.

PROCEDURE: Children without Down syndrome or acute promyelocytic leukemia who were newly diagnosed with primary myelodysplastic syndrome or acute myeloid leukemia (AML) M6 or M7 were compared to children with de novo AML M0-M5.

RESULTS: The presentation and outcomes of the 132 children diagnosed with MDS (60 children), AML FAB M6 (19 children), or AML FAB M7 (53 children) were similar.

Children with AML FAB M7 were diagnosed at a significantly younger age (P = 0.001).

Children with MDS, M6, or M7 had significantly lower white blood cell (WBC) counts (P = 0.001), lower peripheral blast counts (P < 0.001), and an increased frequency of -7/7q- (P = 0.003) at presentation.

All three groups had significantly inferior overall survival (OS) (P < 0.001) and event free survival (P < 0.001) compared with the 748 children diagnosed with AML FAB M0-M5 when assessed from entry on study.

However, when assessed from successful completion of induction therapy, the 5-year OS (P = 0.090)(49.1 vs. 56.9%) and disease-free survival (DFS) (P = 0.113)(38.0 vs. 46.3%) therapy were not significantly different from other children with AML.

CONCLUSIONS: Childhood AML FAB M6 and AML M7 resemble MDS in presentation, poor induction success rates, and outcomes.

[MeSH-major] Leukemia, Erythroblastic, Acute / diagnosis. Leukemia, Megakaryoblastic, Acute / diagnosis. Myelodysplastic Syndromes / diagnosis

[MeSH-minor] Acute Disease. Child. Child, Preschool. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Male. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

Genetic Alliance. consumer health - Myelodysplastic syndromes.

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16856158.001).

[ISSN] 1545-5009

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

METHODS AND RESULTS: Effects of selected cytokines and growth factors on megakaryocyte expression of FcgammaRIIa were assessed with phorbol 12-myristate 13-acetate (PMA)-differentiated human erythroleukemia (HEL) cells and with thrombopoietin-differentiated CD34 stem cells and compared with those obtained with myelocytic cell lines and a monocytic cell lines.

This effect of IFNgamma may contribute to greater platelet expression of FcgammaRIIa in patients with atherosclerotic vascular disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19372459.001).

[ISSN] 1524-4636

[Journal-full-title] Arteriosclerosis, thrombosis, and vascular biology

[ISO-abbreviation] Arterioscler. Thromb. Vasc. Biol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Fc gamma receptor IIA; 0 / Receptors, IgG; 82115-62-6 / Interferon-gamma

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The WW domain containing E3 ubiquitin protein ligase 1 (WWP1) is a homologous to the E6-associated protein C terminus-type E3 ligase frequently overexpressed in human prostate and breast cancers due to gene amplification.

Here, we showed that WWP1 upregulates and maintains erythroblastic leukemia viral oncogene homolog 2 (ErbB2) and epithelial growth factor receptor (EGFR) in multiple cell lines.

[MeSH-major] Genes, erbB-2. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics. Ubiquitin-Protein Ligases / metabolism

[MeSH-minor] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Carrier Proteins / genetics. Carrier Proteins / physiology. Cell Division. Cell Line, Tumor. Cell Survival. Epidermal Growth Factor / physiology. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Gene Amplification. Gene Deletion. Gene Expression Regulation, Neoplastic. Humans. Male. Phosphorylation. Prostatic Neoplasms / genetics. Prostatic Neoplasms / pathology

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18724389.001).

[ISSN] 1476-5594

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] England

[Chemical-registry-number] 0 / Carrier Proteins; 0 / RNF11 protein, human; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 6.3.2.19 / Ubiquitin-Protein Ligases; EC 6.3.2.19 / WWP1 protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The application of this method was tested on ubiquitin-protein conjugates in the brains of Niemann-Pick type C disease mouse and in heat-shocked K562 erythroleukemia cells.

Hazardous Substances Data Bank. SODIUM LAURYL SULFATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18358228.001).

[ISSN] 1096-0309

[Journal-full-title] Analytical biochemistry

[ISO-abbreviation] Anal. Biochem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Detergents; 0 / Membrane Proteins; 0 / Npc1 protein, mouse; 0 / Proteins; 0 / Ubiquitin; 0 / flotillins; 368GB5141J / Sodium Dodecyl Sulfate

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Importantly, during latency, only a small number of viral encoded genes are expressed.

This viral gene expression pattern contributes to the establishment of long-term infection as well as the ability of the virus to evade the immune system.

Previous studies have been shown that the replication and transcription activator (RTA) encoded by ORF50 activates it downstream genes and initiates viral lytic reactivation through functional interaction with RBP-Jkappa, the major downstream effector of the Notch signaling pathway.

This indicates that RTA can usurp the conserved Notch signaling pathway and mimic the activities of intracellular Notch1 to modulate gene expression.

In this report, we show that the activated intracellular domain of Notch1 (ICN) is aberrantly accumulated in KSHV latently infected pleural effusion lymphoma (PEL) cells.

[MeSH-minor] B-Lymphocytes. Cell Line. Gene Expression Regulation, Viral. Humans. Promoter Regions, Genetic. Protein Binding. Sarcoma, Kaposi / metabolism. Sarcoma, Kaposi / virology. Transcriptional Activation

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16701788.001).

[ISSN] 0042-6822

[Journal-full-title] Virology

[ISO-abbreviation] Virology

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA 072510; United States / NCI NIH HHS / CA / CA 091792; United States / NIDCR NIH HHS / DE / DE 01436

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Receptor, Notch1

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) is a Human Herpesvirus-8 (HHV-8)-associated tumor, which releases several cytokines such as IL-6, IL-10 and VEGF and its growth seems to be dependent on them in vitro or in vivo.

The iDC obtained in the presence of PEL supernatants showed reduction of FITC-dextran uptake, reduction of MLR allostimulatory activity and altered expression of surface molecules, suggesting that cytokines released by PEL adversely affect DC differentiation.

Genetic Alliance. consumer health - Primary effusion lymphoma.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18680763.001).

[ISSN] 0165-2478

[Journal-full-title] Immunology letters

[ISO-abbreviation] Immunol. Lett.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / Cytokines

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The characterization of exposure was conducted by means of an extensive survey of several persistent organic pollutants (PAHs, PCBs, DDTs, PBDEs, HCHs, HCB) measured in seven core sediments from the Sunderban wetlands, obtaining a dataset with more than 2200 analyses.

The three different approaches chosen for risk assessment of the Sunderban were the consensus SQGs obtained by TEC (threshold effect concentration), PEC (probable effect concentration) and EEC (extreme effect concentration), the threshold/probable effect level (TEL/PEL) approach and, finally, the ERL-ERM guidelines, including the m-ERM-Q (mean ERM quotient).

A different sensitivity for toxicity assessment due to quality guidelines was obtained, as the consensus SQGs based on TEC were less conservative and protective than the TEL and ERL approaches, while the use of m-ERM-Q seems to be the most powerful tool to predict the toxicity related to a contaminant mixture.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18718633.001).

[ISSN] 1879-1298

[Journal-full-title] Chemosphere

[ISO-abbreviation] Chemosphere

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Soil Pollutants; 0 / Water Pollutants, Chemical

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

NK cells are large granular lymphocytes that represent a critical component of the innate immunity.

Significant numbers of CD56dimCD16+ cytotoxic and CD56-CD16+ immature NK cells appeared in peripheral blood (PB), peritoneal cavity, spleen, bone marrow and liver of the mice.

The NOD/SCID mice engrafted with human NK cells exhibited antitumor activity against K562 erythroleukemia in vitro and in vivo.

[MeSH-minor] Animals. Cell Death / immunology. Cell Line, Tumor. Cells, Cultured. Fetal Blood / cytology. Fetal Blood / transplantation. GPI-Linked Proteins. Humans. Immunity, Innate. K562 Cells. Lymphocyte Activation / immunology. Mice. Mice, Inbred NOD. Mice, SCID. Transduction, Genetic

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16304638.001).

[ISSN] 0014-2980

[Journal-full-title] European journal of immunology

[ISO-abbreviation] Eur. J. Immunol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Antigens, CD; 0 / FCGR3B protein, human; 0 / GPI-Linked Proteins; 0 / Receptors, IgG

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease.

The Kaposi sarcoma-associated herpesvirus (KSHV)-DNA level was determined in samples from 71 patients with Kaposi sarcoma (KS), 28 patients with multicentric Castleman disease (MCD), and 8 patients with primary effusion lymphoma (PEL).

KSHV-DNA levels were higher in patients with active KS or MCD than in those with KS or MCD in remission.

Among patients with active disease, the highest KSHV-DNA levels were observed in effusion fluid samples from patients with PEL (7.2 log(10) copies/150,000 cells), followed by blood samples from patients with MCD and PEL (4.86 and 3.83 log(10) copies/150,000 cells, respectively), and the lowest levels were observed in blood samples from patients with KS (2.63 log(10) copies/150,000 cells).

Determining the KSHV-DNA level may be useful in diagnosing KSHV-associated disease and for following up patients with KS when the development of MCD or PEL is suspected.

[MeSH-minor] Adult. Aged. Aged, 80 and over. Ascitic Fluid / virology. CD4 Lymphocyte Count. Female. HIV Infections / complications. Humans. Male. Middle Aged. Pleural Effusion / virology. Retrospective Studies

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

MedlinePlus Health Information. consumer health - Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17955434.001).

[ISSN] 0022-1899

[Journal-full-title] The Journal of infectious diseases

[ISO-abbreviation] J. Infect. Dis.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNA, Viral

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

In the present study, an improved PM isolation technique involving coating intact cells with synthesized cationic silica-coated magnetic nanospheres was developed and applied to the proteomic analysis of the PM from human erythroleukaemia K562 cells.

[MeSH-minor] Blotting, Western. Cations / chemistry. Cell Line, Tumor. Colloids / chemistry. Humans. Leukemia, Erythroblastic, Acute / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19860738.001).

[ISSN] 1470-8744

[Journal-full-title] Biotechnology and applied biochemistry

[ISO-abbreviation] Biotechnol. Appl. Biochem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Cations; 0 / Colloids; 0 / Membrane Proteins; 7631-86-9 / Silicon Dioxide

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma.

Kaposi's sarcoma-associated herpesvirus (KSHV), also termed human herpesvirus type 8, is consistently identified in Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's disease.

All KSHV-positive solid lymphomas exhibited PEL-like cell morphology.

To investigate the relationship of these disorders to PEL and to other AIDS-associated diffuse large cell lymphomas, KSHV-positive solid lymphomas were tested for the expression of a set of genes that were previously shown by gene profiling analysis to define PEL tumor cells.

The results showed that expression of this set of genes in KSHV-positive lymphomas is similar to that of PEL but distinct from KSHV-negative AIDS-associated diffuse large cell lymphomas.

Because pathobiological features of KSHV-positive solid lymphomas closely mimic those of PEL, our results suggest that KSHV-positive solid lymphomas should be considered as a tissue-based variant of classical PEL, irrespective of HIV status.

Genetic Alliance. consumer health - Primary effusion lymphoma.

MedlinePlus Health Information. consumer health - Lymphoma.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mod Pathol. 2000 Jan;13(1):77-85 [10658913.001]

[Cites] Am J Surg Pathol. 1999 Oct;23(10):1208-16 [10524521.001]

[Cites] Leuk Lymphoma. 1999 Oct;35(3-4):379-87 [10706463.001]

[Cites] AIDS. 2000 Aug 18;14(12):1675-88 [10985303.001]

[Cites] Adv Cancer Res. 2001;80:115-46 [11034542.001]

[Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]

[Cites] J Mol Diagn. 2001 Feb;3(1):32-8 [11227070.001]

[Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]

[Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]

[Cites] AIDS Patient Care STDS. 2002 Apr;16(4):139-45 [12015867.001]

[Cites] Hum Pathol. 2002 Aug;33(8):846-9 [12203218.001]

[Cites] Am J Surg Pathol. 2002 Oct;26(10):1363-7 [12360052.001]

[Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]

[Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]

[Cites] Mod Pathol. 2003 May;16(5):424-9 [12748248.001]

[Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]

[Cites] J Mol Diagn. 2004 Nov;6(4):290-6 [15507667.001]

[Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]

[Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]

[Cites] J Clin Oncol. 1985 Sep;3(9):1202-16 [4031967.001]

[Cites] N Engl J Med. 1993 Feb 4;328(5):327-35 [8093551.001]

[Cites] Lancet. 1993 Feb 13;341(8842):441 [8094208.001]

[Cites] EMBO J. 1993 Dec 15;12(13):4955-67 [8262038.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]

[Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]

[Cites] AIDS. 1996 Aug;10(9):941-9 [8853726.001]

[Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]

[Cites] Int J Cancer. 1997 Oct 9;73(2):303-4 [9335459.001]

[Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]

[Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]

[Cites] Semin Cancer Biol. 1999 Jun;9(3):165-74 [10343068.001]

[Cites] Am J Surg Pathol. 1999 Aug;23(8):992-4 [10435572.001]

[Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]

(PMID = 15681470.001).

[ISSN] 1525-1578

[Journal-full-title] The Journal of molecular diagnostics : JMD

[ISO-abbreviation] J Mol Diagn

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA037295; United States / NCI NIH HHS / CA / R37 CA037295; United States / NCI NIH HHS / CA / CA-37295

[Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Other-IDs] NLM/ PMC1876263

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A chemosensory system that regulates biofilm formation through modulation of cyclic diguanylate levels.

Mutations in a gene called wspF, part of a putative chemosensory signal-transduction operon, have been shown to result in cell aggregation and altered colony morphology.

The WspF phenotypes depend on the presence of WspR, which is a member of a family of signal transduction proteins known as response regulators.

WspR contains a GGDEF domain known to catalyze formation of a cytoplasmic signaling molecule cyclic diguanylate (c-diGMP).

We observed increased cellular levels of c-diGMP and increased biofilm formation in a wspF mutant.

Expression of a protein predicted to catalyze degradation of c-diGMP reversed the phenotypes of a wspF mutant and inhibited biofilm initiation by wild-type cells, indicating that the presence of c-diGMP is necessary for biofilm formation.

A transcriptome analysis showed that expression levels of at least 560 genes were affected by a wspF deletion.

The psl and pel operons, which are involved in exopolysaccharide production and biofilm formation, were expressed at high levels in a wspF mutant.

Together, the data suggest that the wsp signal transduction pathway regulates biofilm formation through modulation of cyclic diguanylate levels.

COS Scholar Universe. author profiles.

Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Bacteriol. 2004 Jul;186(14):4457-65 [15231777.001]

[Cites] J Biol Chem. 2005 Sep 2;280(35):30829-37 [15994307.001]

[Cites] Mol Microbiol. 2004 Aug;53(3):857-69 [15255898.001]

[Cites] Microbiology. 2004 Aug;150(Pt 8):2497-502 [15289546.001]

[Cites] Mol Microbiol. 2004 Aug;53(4):1123-34 [15306016.001]

[Cites] Mol Microbiol. 2004 Oct;54(1):264-77 [15458421.001]

[Cites] J Biol Chem. 1982 Aug 25;257(16):9759-69 [6286632.001]

[Cites] Gene. 1989 Apr 15;77(1):51-9 [2744487.001]

[Cites] J Bacteriol. 1989 Dec;171(12):6649-55 [2556370.001]

[Cites] Microbiol Rev. 1991 Mar;55(1):35-58 [2030672.001]

[Cites] Methods Enzymol. 1993;217:270-9 [8474334.001]

[Cites] Biotechniques. 1993 Nov;15(5):831-4 [8267974.001]

[Cites] Antimicrob Agents Chemother. 1994 May;38(5):1052-8 [8067737.001]

[Cites] J Biol Chem. 1994 Dec 16;269(50):31567-72 [7989325.001]

[Cites] FEBS Lett. 1997 Oct 20;416(2):207-11 [9369216.001]

[Cites] Science. 1998 Apr 10;280(5361):295-8 [9535661.001]

[Cites] Mol Microbiol. 1998 May;28(3):449-61 [9632250.001]

[Cites] Gene. 1998 May 28;212(1):77-86 [9661666.001]

[Cites] Mol Microbiol. 1998 Oct;30(2):295-304 [9791175.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17084-9 [15569936.001]

[Cites] J Bacteriol. 2005 Mar;187(5):1792-8 [15716451.001]

[Cites] Microbiology. 2005 Mar;151(Pt 3):985-97 [15758243.001]

[Cites] Appl Environ Microbiol. 2005 Aug;71(8):4809-21 [16085879.001]

[Cites] Microbes Infect. 2000 Jul;2(9):1051-60 [10967285.001]

[Cites] Proteins. 2001 Feb 1;42(2):210-6 [11119645.001]

[Cites] Trends Microbiol. 2001 Jan;9(1):34-9 [11166241.001]

[Cites] Lancet. 2001 Jul 14;358(9276):135-8 [11463434.001]

[Cites] Microbiology. 2001 Aug;147(Pt 8):2065-75 [11495985.001]

[Cites] FEMS Microbiol Lett. 2001 Oct 16;204(1):163-7 [11682196.001]

[Cites] J Bacteriol. 2002 Feb;184(4):1140-54 [11807075.001]

[Cites] Nature. 2002 Apr 18;416(6882):740-3 [11961556.001]

[Cites] Genetics. 2002 May;161(1):33-46 [12019221.001]

[Cites] Nature. 2002 May 30;417(6888):552-5 [12037568.001]

[Cites] J Bacteriol. 2002 Aug;184(16):4374-83 [12142407.001]

[Cites] J Bacteriol. 2002 Nov;184(21):5946-54 [12374828.001]

[Cites] J Bacteriol. 2002 Dec;184(23):6481-9 [12426335.001]

[Cites] J Bacteriol. 2003 Feb;185(4):1384-90 [12562809.001]

[Cites] Mol Microbiol. 2003 Mar;47(6):1695-708 [12622822.001]

[Cites] J Bacteriol. 2003 Apr;185(7):2066-79 [12644476.001]

[Cites] J Med Microbiol. 2003 Apr;52(Pt 4):295-301 [12676867.001]

[Cites] J Bacteriol. 2003 Sep;185(18):5431-41 [12949095.001]

[Cites] Mol Microbiol. 2003 Oct;50(1):15-27 [14507360.001]

[Cites] Nature. 2003 Nov 20;426(6964):306-10 [14628055.001]

[Cites] Mol Microbiol. 2004 Feb;51(3):675-90 [14731271.001]

[Cites] Mol Microbiol. 2004 Feb;51(4):973-85 [14763974.001]

[Cites] Genes Dev. 2004 Mar 15;18(6):715-27 [15075296.001]

[Cites] Environ Microbiol. 2004 Jun;6(6):546-51 [15142242.001]

[Cites] J Bacteriol. 2004 Jul;186(14):4449-56 [15231776.001]

[Cites] J Bacteriol. 2004 Jul;186(14):4466-75 [15231778.001]

(PMID = 16186483.001).

[ISSN] 0027-8424

[Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America

[ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.

[Language] ENG

[Grant] United States / NIGMS NIH HHS / GM / R01 GM056665; United States / NIGMS NIH HHS / GM / GM056665

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Bacterial Proteins; 147336-22-9 / Green Fluorescent Proteins; 61093-23-0 / bis(3',5')-cyclic diguanylic acid; H2D2X058MU / Cyclic GMP

[Other-IDs] NLM/ PMC1234902

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform.

BACKGROUND: The cDNA-mediated Annealing, extension, Selection and Ligation (DASL) assay has become a suitable gene expression profiling system for degraded RNA from paraffin-embedded tissue.

We examined assay characteristics and the performance of the DASL 502-gene Cancer Panel v1 (1.5K) and 24,526-gene panel (24K) platforms at differentiating nine human epidermal growth factor receptor 2- positive (HER2+) and 11 HER2-negative (HER2-) paraffin-embedded breast tumors.

Unequal-variance t-statistics tested for differences in expression levels between HER2 + and HER2 - tumors.

Inter-panel correlations of expression values for the common 498 genes across the two panels ranged between 0.485-0.573.

In both panels, erythroblastic leukemia viral oncogene homolog 2 (ERBB2) was the most differentially expressed gene between the HER2 + and HER2 - tumors and seven additional genes had p-values < 0.05 and log2 -fold changes > |0.5| in expression between HER2 + and HER2 - tumors: topoisomerase II alpha (TOP2A), cyclin a2 (CCNA2), v-fos fbj murine osteosarcoma viral oncogene homolog (FOS), wingless-type mmtv integration site family, member 5a (WNT5A), growth factor receptor-bound protein 7 (GRB7), cell division cycle 2 (CDC2), and baculoviral iap repeat-containing protein 5 (BIRC5).

The top 52 discriminating probes from the 24K panel are enriched with genes belonging to the regulatory networks centered around v-myc avian myelocytomatosis viral oncogene homolog (MYC), tumor protein p53 (TP53), and estrogen receptor α (ESR1).

Network analysis with a two-step extension also showed that the eight discriminating genes common to the 1.5K and 24K panels are functionally linked together through MYC, TP53, and ESR1.

CONCLUSIONS: The relative RNA abundance obtained from two highly differing density gene panels are correlated with eight common genes differentiating HER2 + and HER2 - breast tumors.

Network analyses demonstrated biological consistency between the 1.5K and 24K gene panels.

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

SciCrunch. ArrayExpress: Data: Microarray .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]

[Cites] Nucleic Acids Res. 2002 Jan 1;30(1):207-10 [11752295.001]

[Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]

[Cites] J Natl Cancer Inst. 2003 Jan 15;95(2):142-53 [12529347.001]

[Cites] Nat Genet. 2003 Jun;34(2):226-30 [12754511.001]

[Cites] Cell Cycle. 2003 Sep-Oct;2(5):415-7 [12963829.001]

[Cites] Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R153-7 [12928487.001]

[Cites] Hum Mol Genet. 2003 Dec 15;12(24):3245-58 [14570715.001]

[Cites] Genome Res. 2004 May;14(5):878-85 [15123585.001]

[Cites] Cancer Cell. 2004 Jun;5(6):607-16 [15193263.001]

[Cites] Am J Pathol. 2004 Nov;165(5):1799-807 [15509548.001]

[Cites] Cancer Res. 1990 Jul 1;50(13):3947-51 [1972345.001]

[Cites] Bioinformatics. 2004 Nov 1;20(16):2778-86 [15166021.001]

[Cites] Clin Chem. 2004 Dec;50(12):2384-6 [15563488.001]

[Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]

[Cites] Am J Clin Pathol. 2005 Apr;123(4):541-6 [15743737.001]

[Cites] Nat Clin Pract Oncol. 2005 May;2(5):246-54 [16264960.001]

[Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]

[Cites] Cancer Res. 2006 Apr 15;66(8):4079-88 [16618727.001]

[Cites] Hum Pathol. 2006 Sep;37(9):1217-26 [16938528.001]

[Cites] Nat Biotechnol. 2006 Sep;24(9):1151-61 [16964229.001]

[Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]

[Cites] Breast Cancer Res. 2006;8(5):214 [17076877.001]

[Cites] Genomics. 2007 Jun;89(6):666-72 [17459658.001]

[Cites] J Natl Cancer Inst. 2007 Nov 21;99(22):1683-94 [18000219.001]

[Cites] Lab Invest. 2008 Apr;88(4):430-40 [18305565.001]

[Cites] Methods Mol Biol. 2008;439:159-77 [18370102.001]

[Cites] JAMA. 2008 Apr 2;299(13):1574-87 [18387932.001]

[Cites] PLoS One. 2008;3(5):e2318 [18846227.001]

[Cites] J Pathol. 2008 Dec;216(4):399-407 [18810758.001]

[Cites] Pathology. 2009 Jan;41(1):77-88 [19089743.001]

[Cites] N Engl J Med. 2009 Feb 19;360(8):790-800 [19228622.001]

[Cites] Gynecol Oncol. 2009 Jul;114(1):3-11 [19410283.001]

[Cites] BMC Bioinformatics. 2009;10 Suppl 11:S12 [19811677.001]

[Cites] PLoS One. 2009;4(12):e8162 [19997620.001]

[Cites] J Pathol. 2010 Aug;221(4):452-61 [20593485.001]

[Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]

[Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]

(PMID = 21172013.001).

[ISSN] 1755-8794

[Journal-full-title] BMC medical genomics

[ISO-abbreviation] BMC Med Genomics

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA129949; United States / NCI NIH HHS / CA / CA129949; United States / NCI NIH HHS / CA / CA150083

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2

[Other-IDs] NLM/ PMC3022545

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] PU.1 directly regulates cdk6 gene expression, linking the cell proliferation and differentiation programs in erythroid cells.

Most leukemia cells are blocked from undergoing terminal differentiation and also exhibit uncontrolled proliferation.

Dysregulated expression of transcription factor PU.1 is strongly associated with Friend virus-induced erythroleukemia.

PU.1 inhibits erythroid differentiation by binding to and inhibiting GATA-1.

PU.1 also may be involved in controlling proliferation of erythroid cells.

We reported previously that the G(1) phase-specific cyclin-dependent kinase 6 (CDK6) also blocks erythroid differentiation.

We now report that PU.1 directly stimulates transcription of the cdk6 gene in both normal erythroid progenitors and erythroleukemia cells, as well as in macrophages.

We propose that PU.1 coordinates proliferation and differentiation in immature erythroid cells by inhibiting the GATA-1-mediated gene expression program and also by regulating expression of genes that control progression through the G(1) phase of the cell cycle, the period during which the decision to differentiate is made.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Cell Biol. 2004 Aug;24(15):6560-8 [15254224.001]

[Cites] Blood. 2004 May 15;103(10):3615-23 [14739214.001]

[Cites] Methods Mol Med. 2005;105:323-44 [15492405.001]

[Cites] Nature. 1986 Apr 24-30;320(6064):760-3 [3458027.001]

[Cites] Nature. 1986 Aug 21-27;322(6081):748-50 [3528861.001]

[Cites] Nature. 1986 Aug 28-Sep 3;322(6082):848-50 [3528863.001]

[Cites] Proc Natl Acad Sci U S A. 1986 Sep;83(17):6480-4 [3529085.001]

[Cites] Nature. 1988 Jan 21;331(6153):277-80 [2827041.001]

[Cites] Cell. 1990 Apr 6;61(1):113-24 [2180582.001]

[Cites] J Biol Chem. 1993 Mar 5;268(7):5014-20 [8095266.001]

[Cites] Genes Dev. 1993 Oct;7(10):2006-15 [8406004.001]

[Cites] Mol Cell Biol. 1994 Jul;14(7):4408-18 [8007948.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2869-73 [7708739.001]

[Cites] Mol Cell Biol. 1995 Oct;15(10):5830-45 [7565736.001]

[Cites] J Exp Med. 1996 Jul 1;184(1):61-9 [8691150.001]

[Cites] Oncogene. 1997 Jan 9;14(1):123-31 [9010239.001]

[Cites] Blood. 1997 Nov 15;90(10):3984-95 [9354667.001]

[Cites] Stem Cells. 1998;16(1):25-37 [9474745.001]

[Cites] EMBO J. 1998 Aug 3;17(15):4456-68 [9687512.001]

[Cites] Genes Dev. 1998 Aug 1;12(15):2403-12 [9694804.001]

[Cites] Curr Opin Genet Dev. 1998 Oct;8(5):545-51 [9794826.001]

[Cites] Genes Dev. 1999 Jun 1;13(11):1398-411 [10364157.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8705-10 [10411939.001]

[Cites] Dev Cell. 2005 Jan;8(1):97-108 [15621533.001]

[Cites] Biochem Biophys Res Commun. 2005 Apr 22;329(4):1288-92 [15766566.001]

[Cites] Ann N Y Acad Sci. 2005 Jun;1044:142-58 [15958708.001]

[Cites] Int J Hematol. 2005 Jun;81(5):368-77 [16158816.001]

[Cites] EMBO J. 2005 Nov 2;24(21):3712-23 [16222338.001]

[Cites] EMBO J. 2007 May 2;26(9):2361-70 [17431401.001]

[Cites] Curr Opin Hematol. 2007 Jul;14(4):307-14 [17534154.001]

[Cites] Mol Cancer Res. 2007 Oct;5(10):1053-62 [17951405.001]

[Cites] Int J Biochem Cell Biol. 2008;40(1):22-7 [17374502.001]

[Cites] Curr Opin Cell Biol. 2007 Dec;19(6):697-704 [18035529.001]

[Cites] Blood. 2000 Apr 15;95(8):2543-51 [10753833.001]

[Cites] J Cell Biochem. 2000 Jun 12;78(4):519-32 [10861849.001]

[Cites] Stem Cells. 1998;16 Suppl 2:79-83 [11012179.001]

[Cites] Blood. 2000 Oct 15;96(8):2755-64 [11023509.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14317-22 [11114185.001]

[Cites] Curr Opin Genet Dev. 2001 Feb;11(1):91-7 [11163157.001]

[Cites] Nat Rev Genet. 2000 Oct;1(1):57-64 [11262875.001]

[Cites] Oncogene. 2002 May 13;21(21):3403-13 [12032778.001]

[Cites] Acta Haematol. 2002;108(4):237-45 [12432220.001]

[Cites] Eur J Immunol. 2003 Jun;33(6):1727-35 [12778491.001]

[Cites] Mol Cell Biol. 2003 Jul;23(14):5031-42 [12832487.001]

[Cites] Oncogene. 2003 Jul 3;22(27):4143-9 [12833137.001]

[Cites] Cancer Res. 2003 Oct 1;63(19):6363-9 [14559825.001]

[Cites] Mol Cell Biol. 2003 Nov;23(21):7460-74 [14559995.001]

[Cites] Leuk Res. 2004 Jan;28(1):83-9 [14630084.001]

[Cites] Blood. 2004 Sep 15;104(6):1873-80 [15166028.001]

(PMID = 19955566.001).

[ISSN] 1083-351X

[Journal-full-title] The Journal of biological chemistry

[ISO-abbreviation] J. Biol. Chem.

[Language] ENG

[Grant] United States / NHLBI NIH HHS / HL / R01 HL078381; United States / NCI NIH HHS / CA / 2P30CA13330; United States / NHLBI NIH HHS / HL / HL078381; United States / NIGMS NIH HHS / GM / 5T32GM07288; United States / NIGMS NIH HHS / GM / T32 GM007288

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / Gata1 protein, mouse; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; 0 / Trans-Activators; 0 / proto-oncogene protein Spi-1; EC 2.7.11.22 / Cdk6 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinase 6

[Other-IDs] NLM/ PMC2823399

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Elevation of clonal serum free light chains in patients with HIV-negative primary effusion lymphoma (PEL) and PEL-like lymphoma.

Genetic Alliance. consumer health - Primary effusion lymphoma.

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19681885.001).

[ISSN] 1365-2141

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Light Chains

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The mechanisms that regulate induction of the antiapoptotic state and mitogenic signals in primary effusion lymphoma (PEL) are not well known.

In efforts to identify novel approaches to block the proliferation of PEL cells, we found that curcumin (diferuloylmethane), a natural compound isolated from the plant Curcuma Ionga, inhibits cell proliferation and induces apoptosis in a dose dependent manner in several PEL cell lines.

Altogether, our findings suggest a novel function for curcumin, acting as a suppressor of JAK-1 and STAT3 activation in PEL cells, leading to inhibition of proliferation and induction of caspase-dependent apoptosis.

Therefore, curcumin may have a future therapeutic role in PEL and possibly other malignancies with constitutive activation of STAT3.

[MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Cell Proliferation / drug effects. Curcumin / pharmacology. Lymphoma / metabolism. Pleural Effusion, Malignant / metabolism. Signal Transduction / drug effects

Genetic Alliance. consumer health - Primary effusion lymphoma.

MedlinePlus Health Information. consumer health - Lymphoma.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CURCUMIN .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16044161.001).

[ISSN] 0950-9232

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Trans-Activators; 9007-43-6 / Cytochromes c; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.010.2 / JAK1 protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Janus Kinase 1; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; IT942ZTH98 / Curcumin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The rationale for this study is based on the observation that alteration of gene transcription represents a very promising approach to control the expression of selected genes and could be obtained using different molecules acting on the interactions between DNA and transcription factors (TFs).

Antiproliferative activity was assayed on different human cell lines, including erythroleukemia K562, B-lymphoid Raji, T-lymphoid Jurkat and erythroleukemia HEL cell lines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16789890.001).

[ISSN] 1573-4064

[Journal-full-title] Medicinal chemistry (Shāriqah (United Arab Emirates))

[ISO-abbreviation] Med Chem

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United Arab Emirates

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; 0 / Plant Extracts; 0 / Transcription Factors; 9007-49-2 / DNA

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's disease.

We screened multiple TLR agonists for their ability to initiate KSHV replication in latently infected PEL.

Agonists specific for TLR7/8 reactivated latent KSHV and induced viral lytic gene transcription and replication.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Science. 2004 Mar 5;303(5663):1526-9 [14976262.001]

[Cites] Science. 2004 Mar 5;303(5663):1529-31 [14976261.001]

[Cites] Am J Trop Med Hyg. 1966 Mar;15(2):244-6 [4286381.001]

[Cites] Am J Epidemiol. 1969 Sep;90(3):255-61 [4309413.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] J Immunol. 1995 Sep 1;155(5):2533-44 [7650383.001]

[Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]

[Cites] J Exp Med. 1996 Jul 1;184(1):283-8 [8691144.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]

[Cites] J Biol Chem. 2005 Apr 1;280(13):12262-70 [15664995.001]

[Cites] Nat Cell Biol. 2005 Jul;7(7):653-64 [15951806.001]

[Cites] Immunity. 2005 Aug;23(2):165-75 [16111635.001]

[Cites] Oncogene. 2005 Nov 21;24(52):7710-9 [16299531.001]

[Cites] Oncogene. 2006 Jan 19;25(3):349-58 [16186807.001]

[Cites] Trends Mol Med. 2006 Apr;12(4):167-76 [16530484.001]

[Cites] J Immunol. 2006 Dec 1;177(11):8164-70 [17114492.001]

[Cites] J Virol. 2008 Jun;82(11):5440-9 [18367536.001]

[Cites] Cell Host Microbe. 2008 Nov 13;4(5):470-83 [18996347.001]

[Cites] J Virol. 2009 Jan;83(1):440-53 [18971266.001]

[Cites] Ann N Y Acad Sci. 2008 Nov;1143:1-20 [19076341.001]

[Cites] J Virol. 2009 Feb;83(3):1474-82 [19019960.001]

[Cites] J Virol. 1999 Dec;73(12):10329-38 [10559351.001]

[Cites] Eur Cytokine Netw. 2000 Sep;11(3):362-71 [11022119.001]

[Cites] Nat Immunol. 2002 Feb;3(2):196-200 [11812998.001]

[Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]

[Cites] J Virol. 2002 Dec;76(23):12242-9 [12414963.001]

[Cites] Cancer Res. 2003 May 1;63(9):2010-5 [12727810.001]

[Cites] Blood. 2003 Aug 1;102(3):956-63 [12689944.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5598-603 [15034168.001]

(PMID = 19564611.001).

[ISSN] 1091-6490

[Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America

[ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / R01 CA109232; United States / NIDCR NIH HHS / DE / DE018281-03; United States / NIAID NIH HHS / AI / T32 AI007419; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / T32 CA009156; United States / NIDCR NIH HHS / DE / R01 DE018281-03; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NIDCR NIH HHS / DE / R01 DE018281; United States / NIAID NIH HHS / AI / F32 AI078735; United States / NCI NIH HHS / CA / R01 CA096500

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Toll-Like Receptor 7; 0 / Toll-Like Receptor 8

[Other-IDs] NLM/ PMC2710638

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Decursin and PDBu: two PKC activators distinctively acting in the megakaryocytic differentiation of K562 human erythroleukemia cells.

Phorbol 12,13-dibutyrate (PDBu) induces the megakaryocytic differentiation of K562 human erythroleukemia cells through PKC activation.

All these results indicate that decursin and phorbol ester are PKC activators distinctively acting in megakaryocytic differentiation and PKC modulation in K562 leukemia cells.

[MeSH-major] Cell Differentiation. Leukemia, Erythroblastic, Acute / pathology. Megakaryocytes / pathology. Phorbol 12,13-Dibutyrate / pharmacology. Protein Kinase C / metabolism. Pyranocoumarins / pharmacology

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15992925.001).

[ISSN] 0145-2126

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzopyrans; 0 / Butyrates; 0 / Pyranocoumarins; 37558-16-0 / Phorbol 12,13-Dibutyrate; 5928-25-6 / decursin; EC 2.7.11.13 / Protein Kinase C

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications.

A polymorphism was demonstrated in the ECP gene, giving rise to a substitution of arginine at position 97 with threonine.

This polymorphism is related to disease development.

The cytotoxic activity was determined against an erythroleukaemia or a small cell lung cancer cell line.

Some of this functional heterogeneity is based on the genetic polymorphism of the ECP gene and some on post-translational modifications.

MedlinePlus Health Information. consumer health - Allergy.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17250693.001).

[ISSN] 0954-7894

[Journal-full-title] Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

[ISO-abbreviation] Clin. Exp. Allergy

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Blood Proteins; EC 3.1.27.- / Eosinophil Cationic Protein

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Sampling, detection, identification, and quantitation of all compounds were readily achieved in times of less than 2 min, with detection limits ranging from 800 parts per trillion to 3 parts per million depending on the analyte.

For all but one analyte, detection limits were well below (3.5-130 times below) permissible exposure limits.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18181580.001).

[ISSN] 0003-2700

[Journal-full-title] Analytical chemistry

[ISO-abbreviation] Anal. Chem.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primers of multiplex PCR were designed to amplify specific regions of the EBV EBNA1, CMV IE2, and KSHV LANA genes.

To assess diagnostic and pre-clinical applications with this method, we utilized KSHV-positive primary effusion lymphoma (PEL) cells, EBV-positive Burkitt's lymphoma cells, CMV-infected fibroblast cells, and clinically prepared peripheral blood leukocytes (PBLs) that had been infected with viruses.

[MeSH-minor] Blood Donors. Cell Line. Cytomegalovirus Infections / diagnosis. Cytomegalovirus Infections / epidemiology. Cytomegalovirus Infections / virology. DNA, Viral / analysis. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / epidemiology. Epstein-Barr Virus Infections / virology. Prevalence. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / virology. Sensitivity and Specificity

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2006 Wiley-Liss, Inc.

(PMID = 17063511.001).

[ISSN] 0146-6615

[Journal-full-title] Journal of medical virology

[ISO-abbreviation] J. Med. Virol.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNA, Viral

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Sequencing of c-Myc coding sequences revealed that c-Myc in KSHV-positive primary effusion lymphoma (PEL) cell lines is wild type in the N-terminal region that regulates c-Myc protein stability.

Despite this, c-Myc in PEL cells is stabilized.

We now show that LANA increases the level of phosphorylated extracellular signal-regulated kinase 1 (ERK1) and increases ERK phosphorylation of c-Myc on Ser62.

LANA-mediated manipulation of c-Myc function is likely to contribute to KSHV-associated tumorigenesis through the induction of c-Myc regulated cellular genes, as well as by the stimulation of cell cycle progression.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

COS Scholar Universe. author profiles.

PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .

Hazardous Substances Data Bank. L-SERINE .

Hazardous Substances Data Bank. L-Threonine .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Virol. 2000 Sep;74(18):8532-40 [10954554.001]

[Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]

[Cites] J Biol Chem. 2006 Sep 22;281(38):28113-21 [16861237.001]

[Cites] Mol Immunol. 2007 Feb;44(6):1352-60 [16828498.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14554-9 [16983096.001]

[Cites] J Virol. 2006 Nov;80(21):10772-86 [16928766.001]

[Cites] J Virol. 2006 Nov;80(22):11178-90 [16928741.001]

[Cites] PLoS Pathog. 2006 Oct;2(10):e116 [17069461.001]

[Cites] Genes Dev. 2000 Oct 1;14(19):2501-14 [11018017.001]

[Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]

[Cites] J Gen Virol. 2000 Nov;81(Pt 11):2645-52 [11038375.001]

[Cites] Virology. 2001 Dec 20;291(2):241-59 [11878894.001]

[Cites] Arch Biochem Biophys. 2002 Apr 15;400(2):151-61 [12054425.001]

[Cites] J Biol Chem. 2002 Jul 26;277(30):27401-11 [12015325.001]

[Cites] J Virol. 2002 Nov;76(22):11677-87 [12388727.001]

[Cites] Science. 2002 Dec 6;298(5600):1911-2 [12471242.001]

[Cites] Semin Cancer Biol. 2003 Feb;13(1):69-76 [12507558.001]

[Cites] J Virol. 2003 Feb;77(4):2779-83 [12552022.001]

[Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]

[Cites] J Virol. 2003 May;77(10):5975-84 [12719589.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5313-8 [12702757.001]

[Cites] J Virol. 2003 Jun;77(11):6188-96 [12743275.001]

[Cites] J Gen Virol. 2003 Jun;84(Pt 6):1451-62 [12771414.001]

[Cites] J Virol. 2003 Jul;77(14):8019-30 [12829841.001]

[Cites] J Virol. 2004 Jan;78(1):294-301 [14671111.001]

[Cites] J Biol Chem. 2003 Dec 19;278(51):51606-12 [14563837.001]

[Cites] Nat Cell Biol. 2004 Apr;6(4):308-18 [15048125.001]

[Cites] J Virol. 2004 Jun;78(12):6585-94 [15163750.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9085-90 [15150404.001]

[Cites] J Virol. 2004 Jul;78(14):7299-310 [15220403.001]

[Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]

[Cites] J Virol. 2004 Sep;78(18):9936-46 [15331727.001]

[Cites] J Virol. 2004 Oct;78(19):10348-59 [15367601.001]

[Cites] Microbes Infect. 2004 Nov;6(13):1212-8 [15488741.001]

[Cites] J Virol. 2004 Nov;78(22):12566-75 [15507644.001]

[Cites] J Biol Chem. 1991 Dec 15;266(35):23521-4 [1748630.001]

[Cites] Oncogene. 1994 Jan;9(1):59-70 [8302604.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]

[Cites] EMBO J. 1999 Feb 1;18(3):717-26 [9927431.001]

[Cites] Mol Cell. 1999 Feb;3(2):169-79 [10078200.001]

[Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]

[Cites] EMBO Rep. 2005 Feb;6(2):177-83 [15678160.001]

[Cites] J Biol Chem. 2005 Feb 4;280(5):3862-74 [15525642.001]

[Cites] Mol Cell. 2005 Jul 22;19(2):159-70 [16039586.001]

[Cites] J Virol. 2005 Aug;79(16):10429-41 [16051835.001]

[Cites] Nature. 2005 Aug 11;436(7052):807-11 [16094360.001]

[Cites] J Pathol. 2006 Jan;208(2):187-98 [16362980.001]

[Cites] Science. 2006 Feb 10;311(5762):856-61 [16469929.001]

[Cites] J Virol. 2006 Mar;80(5):2243-56 [16474132.001]

[Cites] Mol Cell. 2006 Feb 17;21(4):509-19 [16483932.001]

[Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]

[Cites] Oncogene. 2006 Mar 2;25(9):1281-9 [16247449.001]

[Cites] J Virol. 2006 Jun;80(11):5273-82 [16699007.001]

[Cites] J Virol. 2006 Sep;80(18):8909-19 [16940503.001]

[Cites] Semin Cancer Biol. 2006 Aug;16(4):253-64 [16904903.001]

[Cites] Semin Cancer Biol. 2006 Aug;16(4):288-302 [16938463.001]

[Cites] Semin Cancer Biol. 2006 Aug;16(4):275-87 [16945552.001]

[Cites] J Virol. 2007 Apr;81(8):4021-32 [17267510.001]

[Cites] J Virol. 2007 May;81(9):4722-31 [17314169.001]

[Cites] Oncogene. 2007 Jul 26;26(34):4979-86 [17310999.001]

[Cites] J Virol. 2002 Nov;76(22):11596-604 [12388720.001]

[Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]

[Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]

[Cites] Am J Pathol. 2000 Mar;156(3):743-9 [10702388.001]

[Cites] Blood. 2000 Mar 15;95(6):2104-10 [10706881.001]

[Cites] Mol Cell Biol. 2000 Apr;20(7):2423-35 [10713166.001]

[Cites] Mol Cell Biol. 2000 Jun;20(12):4309-19 [10825194.001]

[Cites] Mol Cell Biol. 2000 Aug;20(16):6008-18 [10913183.001]

(PMID = 17634226.001).

[ISSN] 0022-538X

[Journal-full-title] Journal of virology

[ISO-abbreviation] J. Virol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P01 CA113239

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, Viral; 0 / MYC protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / Ubiquitin; 0 / latency-associated nuclear antigen; 2ZD004190S / Threonine; 452VLY9402 / Serine; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.26 / Glycogen Synthase Kinase 3

[Other-IDs] NLM/ PMC2045471

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Epigenetic alteration of the NF-κB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer.

Basal-like breast cancers are triple-negative (estrogen receptor negative, progesterone receptor negative, erythroblastic leukemia viral oncogene homolog 2 (ERBB2) negative) tumors with an aggressive clinical behavior that lacks effective molecular targets for therapy.

Here, we report that enhanced NIK expression, which is exclusively observed in the basal-like subtype rather than the luminal-like subtype or non-tumorigenic mammary epithelial cells, is caused by epigenetic alteration of the NIK gene.

However, histone H3 acetylation levels were up-regulated in the basal-like subtype.

Thus, NIK and genes induced by the NIK-mediated constitutive NF-κB activation could be therapeutic targets of basal-like breast cancer.

[MeSH-major] Breast Neoplasms / genetics. Epigenesis, Genetic. Gene Expression Regulation, Neoplastic / genetics. Protein-Serine-Threonine Kinases / genetics

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

Hazardous Substances Data Bank. AZACITIDINE .

Hazardous Substances Data Bank. VALPROIC ACID .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © 2010 Japanese Cancer Association.

(PMID = 20735436.001).

[ISSN] 1349-7006

[Journal-full-title] Cancer science

[ISO-abbreviation] Cancer Sci.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histones; 0 / NF-kappa B; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 614OI1Z5WI / Valproic Acid; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.25 / NF-kappa B kinase; M801H13NRU / Azacitidine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Glycolytic inhibition by mutation of pyruvate kinase gene increases oxidative stress and causes apoptosis of a pyruvate kinase deficient cell line.

OBJECTIVE: SLC3 is a Friend erythroleukemic cell line established from the Pk-1(slc) mouse, a mouse model of red blood cell type-pyruvate kinase (R-PK) deficiency.

DNA microarray analysis was performed to examine gene-expression profiles between the two transfectants and parental SLC3.

The forced expression of R-PK significantly decreased cells at the sub G0/G1 stage in an expression-level dependent manner.

Microarray analysis showed that proapoptotic genes, such as Bad, Bnip3, and Bnip3l, were downregulated in the transfectants.

In addition, peroxiredoxin 1 (Prdx1) and other antioxidant genes, such as Cat, Txnrd1, and Glrx1 were also downregulated.

CONCLUSION: These results indicated that glycolytic inhibition by R-PK gene mutation augmented oxidative stress in the Friend erythroleukemia cell, leading to activation of hypoxia-inducible factor-1 as well as downstream proapoptotic gene expression.

Thus, R-PK plays an important role as an antioxidant during erythroid differentiation.

[MeSH-minor] Animals. Apoptosis. Cell Line. Cell Line, Tumor. Erythrocytes / enzymology. Flow Cytometry. Genetic Predisposition to Disease. Leukemia, Erythroblastic, Acute. Mice. Oligonucleotide Array Sequence Analysis

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17662887.001).

[ISSN] 0301-472X

[Journal-full-title] Experimental hematology

[ISO-abbreviation] Exp. Hematol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] EC 2.7.1.40 / Pyruvate Kinase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Activation of Prn-p gene and stable transfection of Prn-p cDNA in leukemia MEL and neuroblastoma N2a cells increased production of PrP(C) but not prevented DNA fragmentation initiated by serum deprivation.

We observed that murine erythroleukemia (MEL) cells arrested in phase G(1) undergo transcriptional activation of Prn-p gene.

Here, we explored the potential role of activation of Prn-p gene and cytosolic accumulation of PrP(C) in growth arrest, differentiation, and apoptotic DNA fragmentation by stably transfecting MEL and N2a cells with Prn-p cDNA.

Our results indicate that (a) Induction of terminal differentiation of stably transfected MEL cells led to growth arrest, activation of Prn-p gene, concomitant expression of transfected Prn-p cDNA, suppression of bax gene, cytosolic accumulation of PrP(C), and DNA fragmentation.

(b) similarly, serum deprivation promoted growth arrest, apoptosis/necrosis associated with DNA fragmentation in parental N2a and N2a13 cells that produced relative high level of PrP(C) and not PrP(SC).

These data indicate that activation of Prn-p gene and expression of transfected Prn-p cDNA in cells of both hematopoietic and neuronal origin occurred concomitantly, and led to cytosolic accumulation of PrP(C) and DNA damage induced by serum deprivation.

[MeSH-major] Apoptosis. DNA Fragmentation. Leukemia, Erythroblastic, Acute / metabolism. Neuroblastoma / metabolism. PrPC Proteins / biosynthesis. Prions / biosynthesis. Transcriptional Activation

[MeSH-minor] Animals. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Proliferation. Culture Media, Serum-Free / metabolism. Cytosol / metabolism. Dimethyl Sulfoxide / pharmacology. Flow Cytometry. Gene Expression Regulation, Neoplastic. Mice. RNA, Messenger / biosynthesis. Time Factors. Transfection. Up-Regulation. bcl-2-Associated X Protein / genetics. bcl-2-Associated X Protein / metabolism

MedlinePlus Health Information. consumer health - Neuroblastoma.

Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2007 Wiley-Liss, Inc.

(PMID = 17186498.001).

[ISSN] 0021-9541

[Journal-full-title] Journal of cellular physiology

[ISO-abbreviation] J. Cell. Physiol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Bax protein, mouse; 0 / Culture Media, Serum-Free; 0 / PrPC Proteins; 0 / Prions; 0 / Prnp protein, mouse; 0 / RNA, Messenger; 0 / bcl-2-Associated X Protein; YOW8V9698H / Dimethyl Sulfoxide

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Primary effusion lymphoma (PEL) is a rare lymphoma of B-cell origin, developed in serous cavities.

PEL tumor cells are latently infected with Kaposi sarcoma-associated herpesvirus (KSHV) and in most cases co-infected with Epstein-Barr virus (EBV).

In 15 primary PEL tumors including 10 EBV-positive cases, we analyzed the fused terminal repeat (TR) regions of KSHV episomes using pulsed-field gel electrophoresis and Southern blot.

On the same genomic DNA samples, the cellular clonality was assessed by Southern blot and PCR detection of monoclonal immunoglobulin heavy chain (IGH) VDJ gene rearrangements, associated in the EBV-infected cases, with Southern blot analysis of the fused termini of EBV episomes.

Monoclonal IGH gene rearrangements were detected in 13 tumors using Southern blot, in 11 cases using PCR, and in all cases considering both methods.

However, only 5 PEL tumors were found to be monoclonally infected with KSHV.

We hypothesized that the apparent discrepancy between viral and cellular clonalities in PEL might be due to several phenomena including complex mechanisms of genomic recircularization, insertion of duplicated sequences into the TR region and simultaneous infection of tumor cells with defective KSHV variants.

Genetic Alliance. consumer health - Primary effusion lymphoma.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2005 Wiley-Liss, Inc.

[CommentIn] Int J Cancer. 2006 Oct 1;119(7):1746-8; author reply 1749-50 [16671085.001]

(PMID = 15700304.001).

[ISSN] 0020-7136

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD; 0 / Immunoglobulin Heavy Chains

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Quantitative determination of hexamethylene diisocyanate (HDI), 2,4-toluene diisocyanate (2,4-TDI) and 2,6-toluene diisocyanate (2,6-TDI) monomers at ppt levels in air by alkaline adduct coordination ionspray tandem mass spectrometry.

Once sensitized, some workers could react to isocyanate monomers at concentrations below 1% of the Permissible Exposure Limit of 5 ppb in air.

Currently available methods are not sufficiently sensitive to adequately evaluate isocyanates present at these levels in workplace air.

The analytical method's linearity was measured for a concentration range varying from the limit of detection of 0.04-0.13 ng mL(-1), depending on the monomer, up to approximately 32 ng mL(-1) for every isocyanate monomer, all with correlation coefficients (R(2)) greater than 0.999.

The analytical method's lower limit of quantification combined with an adapted sampling strategy allow the quantification of isocyanate monomers down to 0.04 ppt for an 8 h work shift when a lithium adduct is used, which is more than 300 times lower than the most sensitive method currently available.

This novel method can be used to confirm the very low level of isocyanate monomers for the safe reassignment of sensitized workers and it is also useful for charting the isocyanate dispersion tail in workplace environments.

Hazardous Substances Data Bank. 2,4-TOLUENE DIISOCYANATE .

Hazardous Substances Data Bank. HEXAMETHYLENE DIISOCYANATE .

Hazardous Substances Data Bank. 2,6-TOLUENE DIISOCYANATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15690096.001).

[ISSN] 1464-0325

[Journal-full-title] Journal of environmental monitoring : JEM

[ISO-abbreviation] J Environ Monit

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Cyanates; 0 / Isocyanates; 0I70A3I1UF / 1,6-hexamethylene diisocyanate; 17X7AFZ1GH / Toluene 2,4-Diisocyanate; 91-08-7 / 2,6-diisocyanatotoluene

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The suitability of atmospheric pressure chemical ionization mass spectrometry as sensing instrumentation for the real-time monitoring of low levels of toxic compounds is assessed, especially with respect to public safety applications.

Tandem MS methods were implemented in selected cases for improved selectivity, sensitivity, and limits of detection.

Limits of detection in the parts-per-billion and parts-per-trillion range were achieved for this set of analytes.

In all cases detection limits were well below the compounds' permissible exposure limits (PELs), even in the presence of added complex mixtures of alkanes.

MedlinePlus Health Information. consumer health - Biodefense and Bioterrorism.

MedlinePlus Health Information. consumer health - Chemical Emergencies.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16568176.001).

[ISSN] 0003-2654

[Journal-full-title] The Analyst

[ISO-abbreviation] Analyst

[Language] eng

[Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] England

[Chemical-registry-number] 0 / Air Pollutants; 0 / Chemical Warfare Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

To examine this, we analyzed whether HLA-G5 affects the proliferation of UT7/EPO and HEL erythroleukemia cells and characterized the mechanism by which HLA-G5 influences erythropoietin receptor (EPOR) signaling.

We show that HLA-G5 inhibits the proliferation of UT7/EPO cells, the EPOR signaling of which is similar to that of normal erythroid progenitors.

Involvement of JAK2 in erythroid cell proliferation has been highlighted by the role of JAK2 V617F mutation in polycythemia vera (PV), a myeloproliferative disorder characterized by erythroid lineage overproduction.

Clinical relevance is provided by analysis of PV patients who carry JAK2 V617F mutation, showing that HLA-G5 inhibits the formation of erythropoietin-independent erythroid colonies.

[MeSH-minor] Cell Division / drug effects. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Colony-Forming Units Assay. Erythroid Precursor Cells / drug effects. Erythropoietin / physiology. G1 Phase / drug effects. HLA-G Antigens. Humans. Janus Kinase 2 / antagonists & inhibitors. Janus Kinase 2 / genetics. Janus Kinase 2 / metabolism. Leukemia, Erythroblastic, Acute / pathology. Microspheres. Mutation, Missense. Phosphorylation / drug effects. Point Mutation. Protein Processing, Post-Translational / drug effects. Recombinant Fusion Proteins / pharmacology. STAT3 Transcription Factor / metabolism. STAT5 Transcription Factor / metabolism

Genetic Alliance. consumer health - Polycythemia vera.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18059484.001).

[ISSN] 1476-5551

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I; 0 / Receptors, Erythropoietin; 0 / Recombinant Fusion Proteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / STAT5 Transcription Factor; 11096-26-7 / Erythropoietin; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The cytotoxicity of DON and DONGLU were compared in cell culture using human erythroleukemia cell line K562.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .

Hazardous Substances Data Bank. DEOXYNIVALENOL .

Hazardous Substances Data Bank. Trypan blue .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17507135.001).

[ISSN] 0278-6915

[Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association

[ISO-abbreviation] Food Chem. Toxicol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Coloring Agents; 0 / Glucuronides; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Trichothecenes; 298-93-1 / thiazolyl blue; EC 3.2.1.31 / Glucuronidase; I2ZWO3LS3M / Trypan Blue; JT37HYP23V / deoxynivalenol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Interestingly, gamma-secretase cleaves several proteins including Notch, E-cadherin, CD44 and ErbB-4 (erythroblastic leukemia viral oncogene homolog 4), which are important modulators of angiogenesis.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15878319.001).

[ISSN] 0014-2999

[Journal-full-title] European journal of pharmacology

[ISO-abbreviation] Eur. J. Pharmacol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Carbamates; 0 / Dipeptides; 0 / L 685458; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / N-benzyloxycarbonyl-valyl-leucyl-leucinal; 0 / Oligopeptides; 0 / Protease Inhibitors; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.4.- / Endopeptidases; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.46 / BACE1 protein, human; EC 3.4.23.46 / Bace1 protein, mouse

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Noise exposure and hearing conservation in U.S. coal mines--a surveillance report.

This study examines the patterns and trends in noise exposure documented in data collected by Mine Safety and Health Administration inspectors at U.S. coal mines from 1987 through 2004.

During this period, MSHA issued a new regulation on occupational noise exposure that changed the regulatory requirements and enforcement policies.

The exposure reduction was accompanied by an increase of shift length as represented by dosimeter sample duration.

For coal miners exposed above the permissible exposure level, use of hearing protection devices increased from 61% to 89% during this period.

Participation of miners exposed at or above the action level in hearing conservation programs rapidly reached 86% following the effective date of the noise rule.

MedlinePlus Health Information. consumer health - Occupational Health.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17162478.001).

[ISSN] 1545-9624

[Journal-full-title] Journal of occupational and environmental hygiene

[ISO-abbreviation] J Occup Environ Hyg

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Filopodial protrusions induced by glycoprotein M6a exhibit high motility and aids synapse formation.

M6a is a neuronal membrane glycoprotein whose expression diminishes during chronic stress.

M6a overexpression in rat primary hippocampal neurons induces the formation of filopodial protrusions that could be spine precursors.

As the filopodium and spine motility has been associated with synaptogenesis, we analysed the motility of M6a-induced protrusions by time-lapse imaging.

Our data demonstrate that the motile protrusions formed by the neurons overexpressing M6a were more abundant and moved faster than those formed in control cells.

When different putative M6a phosphorylation sites were mutated, the neurons transfected with a mutant lacking intracellular phosphorylation sites bore filopodia, but these protrusions did not move as fast as those formed by cells overexpressing wild-type M6a.

This suggests a role for M6a phosphorylation state in filopodium motility.

Furthermore, we show that M6a-induced protrusions could be stabilized upon contact with presynaptic region.

The behavior of filopodia from M6a-overexpressing cells and control cells was alike.

Thus, M6a-induced protrusions may be spine precursors that move to reach presynaptic membrane.

We suggest that M6a is a key molecule for spine formation during development.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20074218.001).

[ISSN] 1460-9568

[Journal-full-title] The European journal of neuroscience

[ISO-abbreviation] Eur. J. Neurosci.

[Language] eng

[Grant] United States / Howard Hughes Medical Institute / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] France

[Chemical-registry-number] 0 / Gpm6a protein, rat; 0 / Membrane Glycoproteins; 0 / Nerve Tissue Proteins; 0 / Recombinant Fusion Proteins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Occupational exposure to trichloroethylene is associated with a decline in lymphocyte subsets and soluble CD27 and CD30 markers.

Occupational cohort and case-control studies suggest that trichloroethylene (TCE) exposure may be associated with non-Hodgkin lymphoma (NHL) but findings are not consistent.

Personal exposure measurements were taken over a three-week period before blood collection.

Ninety-six percent of workers were exposed to TCE below the current US Occupational Safety and Health Administration Permissible Exposure Limit (100 p.p.m.

The total lymphocyte count and each of the major lymphocyte subsets including CD4+ T cells, CD8+ T cells, natural killer (NK) cells and B cells were significantly decreased among the TCE-exposed workers compared with controls (P < 0.05), with evidence of a dose-dependent decline.

Further, there was a striking 61% decline in sCD27 plasma level and a 34% decline in sCD30 plasma level among TCE-exposed workers compared with controls.

This is the first report that TCE exposure under the current Occupational Safety and Health Administration workplace standard is associated with a decline in all major lymphocyte subsets and sCD27 and sCD30, which play an important role in regulating cellular activity in subsets of T, B and NK cells and are associated with lymphocyte activation.

[MeSH-major] Antigens, CD27 / blood. Antigens, CD30 / blood. Biomarkers / metabolism. Lymphocyte Subsets / drug effects. Occupational Exposure. Trichloroethylene / adverse effects

[MeSH-minor] Case-Control Studies. Humans. Lymphocyte Count. Molecular Epidemiology

MedlinePlus Health Information. consumer health - Occupational Health.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. Trichloroethylene .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Rheum Dis. 2006 Jun;65(6):796-803 [16284097.001]

[Cites] Exp Hematol. 2005 Dec;33(12):1500-7 [16338493.001]

[Cites] Biomed Environ Sci. 2006 Oct;19(5):346-52 [17190186.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8 [17337643.001]

[Cites] J Neurol Neurosurg Psychiatry. 2008 Sep;79(9):1013-5 [18223013.001]

[Cites] J Occup Environ Med. 2008 Nov;50(11):1306-19 [19001957.001]

[Cites] Immunol Rev. 2009 May;229(1):216-31 [19426224.001]

[Cites] Toxicol Appl Pharmacol. 2009 Jun 1;237(2):188-95 [19332086.001]

[Cites] Environ Health Perspect. 2009 May;117(5):696-702 [19479009.001]

[Cites] J Immunol. 2009 Sep 15;183(6):3770-7 [19710474.001]

[Cites] Toxicol Appl Pharmacol. 2009 Nov 1;240(3):393-400 [19647757.001]

[Cites] Drug News Perspect. 2009 Sep;22(7):409-13 [19890498.001]

[Cites] Transpl Immunol. 2009 Dec;22(1-2):1-4 [19772921.001]

[Cites] Environ Health Perspect. 2000 May;108 Suppl 2:161-76 [10807550.001]

[Cites] Environ Health Perspect. 2000 May;108 Suppl 2:359-63 [10807565.001]

[Cites] Clin Exp Immunol. 2002 Mar;127(3):486-94 [11966765.001]

[Cites] Transpl Int. 2002 Sep;15(8):393-6 [12221457.001]

[Cites] Transpl Immunol. 2003 Oct-Nov;12(1):49-61 [14551032.001]

[Cites] Am J Epidemiol. 2003 Dec 15;158(12):1182-92 [14652303.001]

[Cites] J Autoimmun. 2004 Nov;23(3):211-20 [15501392.001]

[Cites] J Neuroimmunol. 1991 Dec;35(1-3):211-7 [1659587.001]

[Cites] Clin Rheumatol. 1995 May;14(3):293-300 [7641505.001]

[Cites] Toxicol Ind Health. 1995 May-Jun;11(3):253-307 [7482570.001]

[Cites] Environ Health Perspect. 1996 Oct;104 Suppl 5:871-7 [8933028.001]

[Cites] IARC Monogr Eval Carcinog Risks Hum. 1995;63:33-477 [9139128.001]

[Cites] Science. 2004 Dec 3;306(5702):1774-6 [15576619.001]

[Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]

[Cites] J Occup Environ Med. 2005 May;47(5):453-7 [15891523.001]

[Cites] Environ Health Perspect. 2006 Sep;114(9):1471-8 [16966107.001]

(PMID = 20530238.001).

[ISSN] 1460-2180

[Journal-full-title] Carcinogenesis

[ISO-abbreviation] Carcinogenesis

[Language] eng

[Grant] United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NIEHS NIH HHS / ES / P30ES01896; United States / NIEHS NIH HHS / ES / P42ES04705

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, CD27; 0 / Antigens, CD30; 0 / Biomarkers; 290YE8AR51 / Trichloroethylene

[Other-IDs] NLM/ PMC2930801